Hohberger B, Ganslmayer M, Harrer T, Kruse F, Maas S, Borst T, Heimke-Brinck R, Stog A, Knauer T, Rühl E, Zeisberg V, Skornia A, Bartsch A, Ströbel A, Wytopil M, Merkel C, Hofmann S, Schmidt K, Lakatos P, Schottenhamml J, Herrmann M, Mardin C, Rech J (2025)
Publication Language: English
Publication Type: Journal article
Publication year: 2025
Book Volume: 86
Article Number: 103358
DOI: 10.1016/j.eclinm.2025.103358
Background: Rovunaptabin neutralises functional autoantibodies targeting G-Protein coupled receptors (GPCR-fAAbs), observed in patients with Post-COVID syndrome. As we hypothesise an improvement of PCS by rovunaptabin, the aim of reCOVer was to investigate safety, tolerability, and clinical effects of rovunaptabin in PCS patients. Methods: reCOVer is a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical investigator initiated trial with 1350 mg rovunaptabin with additional cross-over at the Universitätsklinikum Erlangen, Germany. The trial was registered in EudraCT, 2022-001781-35. Screening was done between 21·11·2023 and 25·06·2024. Eligible participants (18–80 years) showed GPCR-fAAbs, at least 3/8 defined PCS symptoms persisting ≥3 months after COVID-19 and fatigue as major symptom. Participants were randomly assigned (1:1) to either receive rovunaptabin or placebo at day 0 (d0) and d48 with a follow-up of 28 days, respectively. Primary endpoint was the number of treatment emergent adverse events (TEAE) at d28 (co-primary endpoint: TEAE at d70); secondary endpoint focused on fatigue and quality of life. Findings: Thirty PCS patients were randomised and analysed. RCT analysis showed nine (rovunaptabin) and five TEAEs (placebo), yet without statistically significance (p = 0·1299; CI −14·80%; 63·02%); one serious adverse event, not related to treatment, was recorded. Rovunaptabin showed a neutralisation of GPCR-fAAb and a significant improvement of FACIT Fatigue Scale (effect size = 2·10, p = 0·0378), Bell score (effect size = 3·64, p = 0·0004), Fatigue Severity Scale (effect size = −2·66, p = 0·0088), and quality of life (4/8 items). Interpretation: As this proof-of-concept study showed effects on the patient-centred endpoint PCS and a good safety profil, subsequent studies are needed to confirm these results in a larger cohort. Funding: German Federal Ministry of Education and Research, German Research Foundation.
APA:
Hohberger, B., Ganslmayer, M., Harrer, T., Kruse, F., Maas, S., Borst, T.,... Rech, J. (2025). Safety, tolerability and clinical effects of rovunaptabin, also known as BC007 on fatigue and quality of life in patients with Post-COVID syndrome (reCOVer): a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical trial (RCT). EClinicalMedicine, 86. https://doi.org/10.1016/j.eclinm.2025.103358
MLA:
Hohberger, Bettina, et al. "Safety, tolerability and clinical effects of rovunaptabin, also known as BC007 on fatigue and quality of life in patients with Post-COVID syndrome (reCOVer): a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical trial (RCT)." EClinicalMedicine 86 (2025).
BibTeX: Download